BMS’s Reblozyl (luspatercept) Receives Health Canada Approval for Beta Thalassemia
Shots:
- The approval is based on the P-lll BELIEVE study assessing Reblozyl (luspatercept) + BSC vs PBO + BSC in adult patients with anemia associated with beta-thalassemia requiring regular RBC transfusions
- Result: ≥33% reduction in RBC transfusion with a reduction of ≥2units from 13-24wks. (21.4% vs. 4.5%), results were published in NEJM
- Reblozyl regulate late-stage RBC maturation to potentially reduce the number of regular RBC transfusions and is the first and only erythroid maturation agent approved in Canada
Click here to read full press release/ article | Ref: BMS | Image: MPR